Selective inhibition of fibroblast- and keratinocyte-derived DPP-4/CD26 has been proposed as a therapeutic tool to inhibit skin fibrosis and prevent proliferative scarring and keloid scar formation [124]. This evidence concerns the gene DPP4 and keloid.